These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6127475)

  • 21. Abbott-38579 (synthetic TRH) in the treatment of depression: a controlled study of oral administration.
    Sugerman AA; Mueller PS; Swartzburg M; Rochford J
    Psychopharmacol Bull; 1975 Jan; 11(1):30. PubMed ID: 804708
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthetic thyroid releasing hormone (TRH) administered orally to chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    Psychopharmacol Commun; 1975; 1(2):191-200. PubMed ID: 817373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropathology of late cortical cerebellar atrophy in Japan: distribution of cerebellar change on an autopsy case and review of Japanese cases.
    Tsuchiya K; Ozawa E; Saito F; Irie H; Mizutani T
    Eur Neurol; 1994; 34(5):253-62. PubMed ID: 7995299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protirelin (TRH) in depression.
    Hollister LE; Berger P; Ogle FL; Arnold RC; Johnson A
    Arch Gen Psychiatry; 1974 Oct; 31(4):468-70. PubMed ID: 4214026
    [No Abstract]   [Full Text] [Related]  

  • 25. Spinocerebellar degeneration and neuropeptides.
    Matsuoka Y; Sakurai N
    Jpn J Med; 1989; 28(6):791-3. PubMed ID: 2517445
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical observations on therapeutic applications of thyrotropin-releasing hormone (TRH).
    Sakoda M; Mori H; Yamada A; Kusaka T; Tateiwa M
    Kobe J Med Sci; 1974 Jun; 20(2):65-81. PubMed ID: 4218287
    [No Abstract]   [Full Text] [Related]  

  • 27. [Spinocerebellar degeneration and neuropeptides].
    Matsuoka Y; Sakurai N
    Nihon Naika Gakkai Zasshi; 1989 Dec; 78(12):1705-8. PubMed ID: 2516527
    [No Abstract]   [Full Text] [Related]  

  • 28. The long loop reflex in spinocerebellar degeneration and motor neuron disease--its changes with TRH therapy.
    Touge T; Takeuchi H; Yamada A; Miki H; Nishioka M
    Electromyogr Clin Neurophysiol; 1990; 30(3):131-40. PubMed ID: 2112456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications.
    Fröhlich E; Wahl R
    Front Neuroendocrinol; 2019 Jan; 52():29-43. PubMed ID: 29935915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spinocerebellar degenerations--clinical aspects and new treatment of ataxia.
    Sobue I
    Jpn J Med; 1985 Feb; 24(1):62-7. PubMed ID: 3923240
    [No Abstract]   [Full Text] [Related]  

  • 31. Thyrotropin-releasing hormone in experimental spinal injury: dose response and late treatment.
    Faden AI; Jacobs TP; Smith MT
    Neurology; 1984 Oct; 34(10):1280-4. PubMed ID: 6435011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Motor disabilities and effects of thyrotropin-releasing hormone on ataxia of spinocerebellar degeneration.
    Kimura I; Ohtomo H; Kogure K
    Tohoku J Exp Med; 1983 Apr; 139(4):331-7. PubMed ID: 6408760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis. Committee on Health Care Issues, American Neurological Association.
    Ann Neurol; 1987 Oct; 22(4):541-3. PubMed ID: 3124710
    [No Abstract]   [Full Text] [Related]  

  • 34. [Proceedings: Clinical study of the treatment with TRH. 3. Effect of repeated TRH administration].
    Sakoda M; Kusaka T; Tateiwa M; Mori E; Yamada A
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):413. PubMed ID: 4217726
    [No Abstract]   [Full Text] [Related]  

  • 35. Thyrotropin-releasing hormone: differential antidepressant and endocrinological effects.
    Furlong FW; Brown GM; Beeching MF
    Am J Psychiatry; 1976 Oct; 133(10):1187-90. PubMed ID: 823828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of low-dose TRH on cognitive deficits in the ECT postictal state.
    Khan A; Mirolo MH; Claypoole K; Bhang J; Cox G; Horita A; Tucker G
    Am J Psychiatry; 1994 Nov; 151(11):1694-6. PubMed ID: 7943463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind crossover sequential trial of oral thyrotrophin-releasing hormone in depression.
    Mountjoy CQ; Price JS; Weller M; Hunter P; Hall R; Dewar JH
    Lancet; 1974 May; 1(7864):958-60. PubMed ID: 4133645
    [No Abstract]   [Full Text] [Related]  

  • 38. Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone.
    Kastin AJ; Ehrensing RH; Schalch DS; Anderson MS
    Lancet; 1972 Oct; 2(7780):740-2. PubMed ID: 4116150
    [No Abstract]   [Full Text] [Related]  

  • 39. [The influence of thyrotrophin-releasing hormone (TRH) on depression in the alcohol withdrawal syndrome (author's transl)].
    Loosen PT; Wilson IC; Lara PP; Prange AJ; Pettus C
    Arzneimittelforschung; 1976; 26(6):1164-6. PubMed ID: 822858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyrotropin-releasing hormone for prevention of neonatal respiratory disease.
    Ballard RA; Ballard PL; Cnaan A; Pinto-Martin J
    Lancet; 1995 Jun; 345(8964):1572. PubMed ID: 7791458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.